Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1993 1
1994 1
1995 3
1998 1
1999 2
2000 2
2001 7
2002 5
2003 3
2004 7
2005 12
2006 12
2007 11
2008 17
2009 9
2010 9
2011 11
2012 7
2013 2
2014 9
2015 6
2016 2
2017 6
2018 7
2019 5
2020 3
2021 4
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, Biemond BJ, Breems DA, Maertens J, van Marwijk Kooy M, Pabst T, de Weerdt O, Ossenkoppele GJ, van de Loosdrecht AA, Huls GA, Cornelissen JJ, Beverloo HB, Löwenberg B, Jongen-Lavrencic M, Valk PJM. Grob T, et al. Among authors: beverloo hb. Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472. Blood. 2022. PMID: 35108372 Free PMC article.
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F, Zwaan CM. Pennesi E, et al. Among authors: beverloo hb. Leukemia. 2022 Jun;36(6):1516-1524. doi: 10.1038/s41375-022-01576-3. Epub 2022 Apr 25. Leukemia. 2022. PMID: 35468945 Free PMC article. Clinical Trial.
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, van der Velden V, Beverloo HB, Bierings M, Dors N, de Haas V, Hoogerbrugge P, Van der Sluis I, Tissing W, Veening M, Boer J, Den Boer M. Pieters R, et al. Among authors: beverloo hb. J Clin Oncol. 2023 Sep 1;41(25):4130-4142. doi: 10.1200/JCO.22.02705. Epub 2023 Jul 17. J Clin Oncol. 2023. PMID: 37459571
The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S, Mulet-Lazaro R, Erpelinck-Verschueren C, van Herk S, Havermans M, Arricibita Varea A, Vermeulen M, Beverloo HB, Gröschel S, Haferlach T, Haferlach C, J Wouters B, Bindels E, Smeenk L, Delwel R. Ottema S, et al. Among authors: beverloo hb. Nat Commun. 2021 Sep 28;12(1):5679. doi: 10.1038/s41467-021-25862-3. Nat Commun. 2021. PMID: 34584081 Free PMC article.
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.
Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B, Foot N, Jeffries S, Martin K, O'Connor S, Schoumans J, Talley P, Telford N, Stioui S, Zemanova Z, Hastings RJ. Rack KA, et al. Among authors: beverloo hb. Leukemia. 2019 Aug;33(8):1851-1867. doi: 10.1038/s41375-019-0378-z. Epub 2019 Jan 29. Leukemia. 2019. PMID: 30696948 Free PMC article. Review.
Recurrently affected genes in juvenile myelomonocytic leukaemia.
Obenauer JC, Kavelaars FG, Sanders MA, de Vries ACH, de Haas V, Beverloo HB, De Moerloose B, Lammens T, Dworzak M, Hoogenboezem RM, Valk PJM, Touw IP, van den Heuvel-Eibrink MM. Obenauer JC, et al. Among authors: beverloo hb. Br J Haematol. 2018 Jul;182(1):135-138. doi: 10.1111/bjh.14737. Epub 2017 May 9. Br J Haematol. 2018. PMID: 28485469 Free article. No abstract available.
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial.
Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, Sleight B, Locatelli F, Brethon B, Rossig C, Engstler G, Nilsson A, Bruno B, Petit A, Bielorai B, Rizzari C, Rialland F, Rubio-San-Simón A, Sirvent FJB, Diaz-de-Heredia C, Rives S, Zwaan CM. Pennesi E, et al. Among authors: beverloo hb. Haematologica. 2024 Jan 4. doi: 10.3324/haematol.2023.284409. Online ahead of print. Haematologica. 2024. PMID: 38186333 Free article.
Hypereosinophilic syndrome in children.
van Grotel M, de Hoog M, de Krijger RR, Beverloo HB, van den Heuvel-Eibrink MM. van Grotel M, et al. Among authors: beverloo hb. Leuk Res. 2012 Oct;36(10):1249-54. doi: 10.1016/j.leukres.2012.05.025. Epub 2012 Jun 22. Leuk Res. 2012. PMID: 22727506
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
Hofste Op Bruinink D, Kuiper R, van Duin M, Cupedo T, van der Velden VHJ, Hoogenboezem R, van der Holt B, Beverloo HB, Valent ET, Vermeulen M, Gay F, Broijl A, Avet-Loiseau H, Munshi NC, Musto P, Moreau P, Zweegman S, van de Donk NWCJ, Sonneveld P. Hofste Op Bruinink D, et al. Among authors: beverloo hb. J Clin Oncol. 2022 Sep 20;40(27):3132-3150. doi: 10.1200/JCO.21.01217. Epub 2022 Mar 31. J Clin Oncol. 2022. PMID: 35357885 Free PMC article.
149 results